Discoidin Domain Receptor



Discoidin domain receptors (DDRs) are receptor tyrosine kinases with the unique ability among receptor tyrosine kinases to respond to collagen. Several signaling molecules have been implicated in DDR signaling, including Shp-2, Src, and MAPK pathways. DDRs have been reported to induce the expression of various genes including matrix metalloproteinases and bone morphogenetic proteins, but the regulatory mechanisms underlying DDR-induced gene expression remain to be determined. DDRs regulate cell-collagen interactions in normal and pathological conditions and thus are emerging as major sensors of collagen matrices and potential novel therapeutic targets.

Discoidin Domain Receptor Inhibitors & Modulators

DDR Inhibitor

Cat. No.: HY-W018931

Bioactivity: DDR Inhibitor is a potent **discoidin domain receptor (DDR)** inhibitor, with an **IC_{50}** of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM.

Purity: 97.85%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



DDR1-IN-1

Cat. No.: HY-13979

Bioactivity: DDR1-IN-1 is a potent and selective **DDR1 receptor tyrosine kinase** inhibitor with an **IC_{50}** of 105 nM; 4-fold less potent for DDR2 (IC_{50} = 413 nM) [1].

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



DDR1-IN-1 dihydrochloride

Cat. No.: HY-13979A

Bioactivity: DDR1-IN-1 dihydrochloride is a potent and selective **DDR1 receptor tyrosine kinase** inhibitor with an **IC_{50}** of 105 nM; 4-fold less potent for DDR2 (IC_{50} = 413 nM) [1].

Purity: >98%
Clinical Data: No Development Reported
Size:



DDR1-IN-2

Cat. No.: HY-U00444

Bioactivity: DDR1-IN-2 is a potent inhibitor of **discoidin domain receptor 1** (**DDR1**), with an **IC_{50}** of 13.1 nM, and also less potently inhibits DDR2, with an **IC_{50}** of 203 nM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



DDR1-IN-3

Cat. No.: HY-100695

Bioactivity: DDR1-IN-3 is a selective Discoidin Domain Receptor 1 **(DDR1)** inhibitor, with an **IC_{50}** value of 9.4 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Sitravatinib

(MGCD516; MG516)

Cat. No.: HY-16961

Bioactivity: Sitravatinib (MGCD516; MG516) is an orally bioavailable, **receptor tyrosine kinase (RTK)** inhibitor with **IC_{50}**s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT , FLT3, DD...

Purity: 99.85%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg